1 Dept of Respiratory Medicine, Royal Devon and Exeter Hospital, University of Exeter, Exeter, UK matthew.masoli@nhs.net.
2 Faculty of Health, University of Plymouth, Plymouth, UK.
3 Plymouth Marjon University, Plymouth, UK.
4 Dept of Respiratory Medicine, Royal Brompton Hospital, London, UK.
5 Dept of Respiratory Medicine, Heartlands Hospital, University Hospitals Birmingham and University of Birmingham, Birmingham, UK.
6 School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
7 Academic Respiratory Unit, University of Bristol, Southmead Hospital, North Bristol Hospital Trust, Bristol, UK.
8 Dept of Respiratory Medicine, University Hospitals Plymouth NHS Trust, Plymouth, UK.
9 College of Medicine and Health, University of Exeter, Exeter, UK.
The Severe Asthma Questionnaire (SAQ) is sensitive to change and clinically significant improvement was detected within 4 weeks of starting biologic therapy. The MCID of the SAQ is 0.5 and of the SAQ-global is 11.https://bit.ly/3poJqcG